Menu ×

HEALTHCARE & PHARMACEUTICAL

Positive Allosteric Modulators Market Segmentation by Disease Type (Parkinson’s disease, Schizophrenia, Alzheimer’s disease, and Others); by Drug Type {Galantamine, Benzodiazepines (Diazepam, Clonazepam, Lorazepam, and Others), Barbiturates (Methohexital, Phenobarbital, and Secobarbital), Amantadine, Donepezil, Levodopa, and Others}; and by End-User (Hospital, Pharmacy, and Others) – Global Demand Analysis & Opportunity Outlook 2031

  • Text Size:

Extensive insights into the Growth of Positive Allosteric Modulators Market amidst COVID-19

Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.

Request Insights


IN THE NEWS

  • February 16, 2022: Acadia Pharmaceuticals Inc. announced the FDA submission of supplemental New Drug Application (sNDA) for Pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

  • June 11, 2020: Interim HealthCare Inc., launched a free dementia caregiver’s guide for homecare for patients living with dementia or Alzheimer’s disease.

Global Positive Allosteric Modulators Market Highlights over 2022 – 2031

The global positive allosteric modulators market is estimated to grow at a significant CAGR over the forecast period, i.e., 2022 – 2031. Allosteric modulators are substances that bind to a receptor to change the receptor's response to stimulus. Positive allosteric modulators function to facilitate agonist-mediated response. The growth of the market can be attributed to the increasing prevalence of mental disorders, such as, dementia, schizophrenia, and others, as positive allosteric modulators are used as a novel treatment approach for the patients. Positive allosteric modulators can be provided to the patients in combination with their currently approved anti-AD drugs, to improve the efficacy of the drugs. The growing cases of Alzheimer’s disease is anticipated to primarily drive the market growth. As per the data by the World Health Organization (WHO), 55 million people live with dementia worldwide, as of 2020, and there are nearly 10 million new cases every year. Out of these 60-70% cases are of Alzheimer’s disease. Moreover, allosteric modulators are also used for medical research and development of new drugs. As per the data by the World Bank, 9.858% of the global gross domestic product (GDP) was spent on healthcare, while research and development expenditure amounted to 2.203% of the GDP in 2018.

Positive Allosteric Modulators Market GraphThe market is segmented by disease type into Parkinson’s disease, schizophrenia, Alzheimer’s disease, and others out of which, the Alzheimer’s disease segment is anticipated to hold a substantial share in the global positive allosteric modulators market over the forecast period on account of high prevalence of the disorder across the globe. Meanwhile, the Parkinson’s disease segment is also estimated to hold a notable size in the market during the forecast period, owing to the ongoing growth in the cases of the disease. According to the statistics by the Parkinson’s Foundation, more than 10 million people are living with this disorder globally. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita Image

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Positive Allosteric Modulators Market Regional Synopsis

On the basis of geographical analysis, the global positive allosteric modulators market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness modest growth over the forecast period on the back of the increasing investment in development of healthcare sector in the region, along with growing health awareness amongst the population.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of the higher health awareness amongst the population, along with easy access of quality healthcare in the developed nations, such as, the United States. Moreover, the higher investment in the R&D activities in the region is further expected to boost the market growth. As per the World Bank data, 2.734% of GDP of North America was spend for R&D activities in 2018.

Positive Allosteric Modulators Market Share Image

The global positive allosteric modulators market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global positive allosteric modulators market includes the following segments:

By Disease Type

  • Parkinson’s disease
  • Schizophrenia
  • Alzheimer’s disease
  • Others

By Drug Type

  • Galantamine
  • Benzodiazepines
    • Diazepam
    • Clonazepam
    • Lorazepam
    • Others
  • Barbiturates
    • Methohexital
    • Phenobarbital
    • Secobarbital
  • Amantadine
  • Donepezil
  • Levodopa
  • Others

By End-User

  • Hospital
  • Pharmacy
  • Others

Growth Drivers

  • Increasing Prevalence of Severe Mental Disorders
  • Growing Medical Research and Development Activities

Challenges

  • Side Effects of the Drugs
  • Poor Adoption of Advanced Technology in Low-income Regions

Top Featured Companies Dominating the Market

  • Acadia Pharmaceuticals Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Eli Lilly and Company
  • Novartis AG
  • Bayer AG
  • Sanofi-aventis Groupe
  • Abbott Laboratories
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Siemens Healthcare GmbH
  • Pfizer Inc.

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved